Naslov
New drugs for the treatment of lymphoma

Autori
Paoluzzi, L. ; Kitagawa, Y, ; Kalac, Matko ; Zain, J. ; O'Connor, O.A.

Izvornik
Hematology - oncology clinics of North America (0889-8588) 22 (2008), 5; 1007-1035

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
new drugs; Bcl-2. Lymphoma. Syk; pralatrexate; B-cell lymphoma; Bcl-2 family proteins; refractory hematologic malignancies; rapamycin inhibitor everolimus; efficiently induces apoptosis; acute lymphoblastic-leukemia; small-molecule inhibitor; pancreatic-cancer cells; structure-based design; Bh3 mimetic abt-737

Sažetak
Historically, most drugs developed for treatment of leukemias, lymphomas, and myeloma had already been studied in the solid tumor setting. Nearly 10 years ago, chronic myelogenous leukemia (CML) forever changed this paradigm. Imatinib showed that it was possible to nullify the pathognomic genetic lesion in a hematologic malignancy. Since the approval of imatinib for CML, a host of new drugs active in blood cancers have emerged. This article highlights some areas of innovative drug development in lymphoma where possible ; it emphasizes the biologic basis for the approach, linking this essential biology to the biochemical pharmacology. The article focuses on the many new targets including Syk, Bcl-2, CD-40, and the phosphoinositide-3 kinase/AKT/mammalian target of rapamycin pathway.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA